WASHINGTON, Feb. 6, 2017 /PRNewswire/ -- At the SLAS
2017 International Conference & Exhibition (www.slas2017.org),
Bruker today announced its new MALDI PharmaPulse 2.0
solution (MPP 2.0), which significantly enhances the automation
capabilities of the rapifleX MALDI-TOF mass
spectrometer, with its proprietary scanning 10 kHz solid-state
laser technology, for label-free, uHTS assays in pharmaceutical
drug discovery. MPP 2.0 enables pharma scientists to
automate MALDI methods development to screen millions of compound
chemical libraries using 384, 1536, 3072 or 6144-well microtiter
format MALDI sample plates.
The new MALDI PharmaPulse 2.0 solution can measure up to
10 different samples per second, a 100- to 1000-fold increase in
speed and throughput for mass spectrometry-based, label-free
screening. The MPP 2.0 solution is compatible with the
latest 1536 simultaneous liquid spotters, and fully integrated
automation solutions for uHTS, e.g. by HighRes Biosolutions
(www.highresbio.com), or others.
The MPP 2.0 solution incorporates an Assay Development
module and a Screening module. The Assay Development module
harnesses the speed of the rapifleX MALDI PharmaPulse
in a multi-dimensional approach, performing serial dilutions,
mixing different buffer concentrations and other assay components
and uses a proprietary algorithm to identify the optimum assay
conditions. The Screening module synchronizes with external
lab automation protocols to seamlessly integrate with the symphony
of robotics required to perform fully automatic, ultra-high speed
screening campaigns.
The GSK (GlaxoSmithKline plc, UK) Platform Technology and
Science group will present data at SLAS 2017 (Haslam et al. Poster
1194, Tuesday 1-3 pm). The Poster
shows the application of rapifleX MALDI PharmaPulse 2.0
coupled with a nanoliter 1536 simultaneous
pipettor (CyBio® Well vario, Analytik Jena) for the
rapid analysis of low volume, 1536-well enzyme assays. The GSK work
demonstrates an automated workflow that enables sample plate
preparation and analysis in just 8-10 minutes. The workflow
illustrates the advantages of label-free mass spectrometry (MS)
detection when coupled with the kind of ultra-high throughput that
is typically associated with fluorescence-based detection. The data
clearly shows the potential for true high throughput screening by
MS.
Dr. Meike Hamester, Director of
the Pharmaceutical Business Unit at Bruker Daltonics, commented:
"The new MALDI PharmaPulse 2.0 user interface was developed
in cooperation with scientists for seamless integration of mass
spectrometry with uHTS robotics routinely used in the
pharmaceutical industry. The unambiguous nature of direct mass
measurement for primary screens, the enormous cost savings with
label-free detection and just nanoliter sample consumption, coupled
to smart software, significantly enhances the utility of the
MALDI PharmaPulse 2.0 solution."
She continued: "We were very pleased with several key MPP
2.0 orders from major pharma companies on both sides of the
Atlantic in the fourth quarter of 2016, and we believe that the
MPP 2.0 solution will become a commercial success in 2017
and beyond. First installations of the new rapifleX MALDI
PharmaPulse 2.0 at Boehringer Ingelheim in Biberach,
Germany and at Genentech in
San Francisco, CA (USA) were
already successfully completed in late 2016."
Professor Matthias Trost at The
Institute for Cell and Molecular Bioscience (ICaMB) of Newcastle University, UK, stated: "The novel
laser technology, digitizer and generally improved instrument
performance of the rapifleX massively increases speed and
signal-to-noise compared to previous instruments. These
features make it the instrument of choice for high-throughput
MALDI-TOF mass spectrometry in drug discovery."
To learn more, please attend the SLAS 2017 Technical
Seminar on Tuesday, February
7th, 2017 from 9:30–10:15 am ET in Room
151A of the Walter E. Washington Convention Center for an
informative tutorial on High-Throughput Screening presented by
Melanie Leveridge, the Director,
Screening Profiling and Mechanistic Biology, at the GSK Medicines
Research Centre in Stevenage, UK,
presenting: 'Further Advancements in MALDI-TOF Mass Spectrometry
towards Ultra High Throughput Screening using the Bruker rapifleX
System and 1536 Parallel Pipetting,' and the talk by Swen
Tyrasa, Head of Automation at Analytik Jena in Jena, Germany: 'Overcome Bottlenecks in MALDI
Sample Plate preparation – 1536 Parallel Pipetting – beyond just
spotting.'
About the rapifleX MALDI Time-of-Flight Mass
Spectrometer
The rapifleX MALDI-TOF mass spectrometer
is the heart of the MALDI PharmaPulse 2.0 solution. It
is the only MALDI mass spectrometer with unique and proprietary 10
kHz scanning laser technology and measures up to 10 samples per
second. The enhanced sensitivity and exceptional
robustness-by-design allow unattended operation during pharma
primary screening campaigns. All performance characteristics of the
rapifleX MALDI TOF and TOF/TOF instruments surpass
anything seen before.
About Bruker Corporation (NASDAQ: BRKR)
For more than
50 years, Bruker has enabled scientists to make breakthrough
discoveries and develop new applications that improve the quality
of human life. Bruker's high-performance scientific research
instruments and high-value analytical solutions enable scientists
to explore life and materials at molecular, cellular and
microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
Investor
Contact:
|
Media
Contact:
|
Miroslava
Minkova
|
Dr. Petra
Scheffer
|
Head of Investor
Relations
|
Bruker Daltonics
Director of MarCom
|
T: +1 (978) 663–3660,
ext. 1479
|
T: +49 (421) 2205
2843
|
E:
miroslava.minkova@bruker.com
|
E:
petra.scheffer@bruker.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-introduces-maldi-pharmapulse-20-solution-at-slas-2017-for-100x-faster-mass-spectrometry-based-label-free-screening-in-drug-discovery-300402229.html
SOURCE Bruker Corporation